Thrombectomy was Penumbra’s largest product and service line in fiscal 2025, bringing in $947.92M of $1.40B (68%).
| Product and Service | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombectomy | $511.14M | $677.34M | $815.48M | $947.92M | |||||||||
| Embolization & Other | $336.00M | $381.18M | $379.14M | $455.75M | |||||||||
| Neuro | — | — | — | — | |||||||||
| Vascular | — | — | — | — | |||||||||
| Peripheral Vascular | — | — | — | — | |||||||||
| Total | $847.13M | $1.06B | $1.19B | $1.40B |
Penumbra brought in $1.40B from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 17.5% from $1.19B in fiscal 2024. Thrombectomy was the largest at $947.92M (67.5%), ahead of Embolization & Other at $455.75M (32.5%).
Compared with fiscal 2024, Embolization & Other grew 20.2% to $455.75M and Thrombectomy grew 16.2% to $947.92M. From fiscal 2022 to 2025, combined revenue from these lines grew from $847.13M to $1.40B, a compound annual growth rate of 18.3%. Thrombectomy's share of the total rose from 60.3% to 67.5%.
United States was Penumbra’s largest region in fiscal 2025, bringing in $1.09B of $1.40B (78%).
| Geography | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $591.72M | $757.15M | $902.07M | $1.09B | |||||||||
| International | $255.42M | $301.37M | $292.55M | $311.90M | |||||||||
| Other International | — | — | — | — | |||||||||
| Japan | — | — | — | — | |||||||||
| Total | $847.13M | $1.06B | $1.19B | $1.40B |
Penumbra brought in $1.40B from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 17.5% from $1.19B in fiscal 2024. United States was the largest at $1.09B (77.8%), ahead of International at $311.90M (22.2%).
Compared with fiscal 2024, United States grew 21.0% to $1.09B and International grew 6.6% to $311.90M. From fiscal 2022 to 2025, combined revenue from these regions grew from $847.13M to $1.40B, a compound annual growth rate of 18.3%. United States' share of the total rose from 69.8% to 77.8%.
Penumbra (PEN) reports its revenue by product and service and by geography. In fiscal 2025, Thrombectomy was its largest product and service line, bringing in $947.92M (67.5% of the total), followed by Embolization & Other at $455.75M (32.5%).
Thrombectomy was Penumbra's largest product and service line in fiscal 2025, bringing in $947.92M, or 67.5% of the $1.40B total across its two product and service lines.
United States was Penumbra's largest region in fiscal 2025, bringing in $1.09B, or 77.8% of the $1.40B total across its two regions.
Embolization & Other grew faster than Thrombectomy in fiscal 2025, up 20.2% from $379.14M to $455.75M. Thrombectomy grew 16.2% to $947.92M.
Every figure comes from Penumbra's annual financial filings, as reported. Each line keeps the name Penumbra gives it, and years follow its fiscal calendar.
Penumbra's revenue by product and service goes back to fiscal 2013, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.